Global

Jun 18, 2018
Pharmaceutical Executive
Weighing the crossover effect of US’s new pricing blueprint. 
Jun 01, 2018
The PD-1/PD-L1 market in China is heating up and companies there have made a series of advances, writes Jin Zhang.
May 16, 2018
Pharmaceutical Executive
Pair of EU meetings, while well-meant, offered little action and beg the question—what’s the true merit in working together?
May 14, 2018
Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.
May 11, 2018
Jin Zhang identifies the major domestic companies in China’s IVD industry.
May 03, 2018
Despite the uncertainty, there is plenty of work to be done to reduce risk in supply chains ahead of the UK’s exit from the European Union, write Johnathon Marshall and Chris Cartmell.
Apr 23, 2018
Jin Zhang discusses the research and development of several major biologics in China.
Apr 07, 2018
Jin Zhang looks at how China's CART-T therapy race is heating up.
Mar 22, 2018
Jin Zhang looks at the Chinese pharma companies that received FDA ANDA approvals in 2017 and discusses how the country's industry is poised for further breakthrough.
Mar 21, 2018
Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills.
native1_300x100
lorem ipsum